• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Novel Targeted Therapies for Advanced Cholangiocarcinoma.晚期胆管癌的新型靶向治疗
Medicina (Kaunas). 2021 Feb 26;57(3):212. doi: 10.3390/medicina57030212.
2
Cholangiocarcinoma miscoding in hepatobiliary centres.肝胆中心胆管癌错配。
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
3
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?双 HER2 阻断：转移性胆道癌的新选择？
Medicina (Kaunas). 2021 Nov 27;57(12):1301. doi: 10.3390/medicina57121301.
4
The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.肝吸虫相关胆管癌的特征：药物靶点的可能性洞察。
Recent Results Cancer Res. 2023;219:53-90. doi: 10.1007/978-3-031-35166-2_4.
5
Clinical presentation, diagnosis and staging of cholangiocarcinoma.胆管癌的临床表现、诊断和分期。
Liver Int. 2019 May;39 Suppl 1:98-107. doi: 10.1111/liv.14086. Epub 2019 Mar 25.
6
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.肝内和肝外胆管癌的危险因素：系统评价和荟萃分析。
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
7
Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.德国胆管癌：流行病学趋势和分类错误的影响。
Liver Int. 2019 Feb;39(2):316-323. doi: 10.1111/liv.13954. Epub 2018 Oct 8.
8
Emerging molecular therapeutic targets for cholangiocarcinoma.胆管癌的新兴分子治疗靶点。
J Hepatol. 2017 Sep;67(3):632-644. doi: 10.1016/j.jhep.2017.03.026. Epub 2017 Apr 5.
9
[Cholangiocarcinoma-diagnosis, classification, and molecular alterations].[胆管癌——诊断、分类及分子改变]
Pathologe. 2020 Sep;41(5):488-494. doi: 10.1007/s00292-020-00808-6.
10
Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.肝内胆管癌合并原发性硬化性胆管炎患者的肿瘤分期与总生存期——一项回顾性队列研究
Z Gastroenterol. 2024 Jan;62(1):37-42. doi: 10.1055/a-2207-5519. Epub 2024 Jan 9.

引用本文的文献

1
Cystic Duct Carcinoma: A New Classification System and the Clinicopathological Features of 62 Patients.胆囊管癌：一种新的分类系统及62例患者的临床病理特征
Front Oncol. 2021 Jun 11;11:696714. doi: 10.3389/fonc.2021.696714. eCollection 2021.
2
Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.晚期胆管癌的靶向治疗：聚焦 FGFR 抑制剂。
Medicina (Kaunas). 2021 May 8;57(5):458. doi: 10.3390/medicina57050458.

本文引用的文献

1
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.PD-L1、肿瘤突变负荷、微卫星不稳定性及其他胆管癌中免疫检查点抑制剂反应的预测指标
Cancers (Basel). 2021 Feb 1;13(3):558. doi: 10.3390/cancers13030558.
2
Immunotherapies in clinical development for biliary tract cancer.正在临床开发中的用于胆管癌的免疫疗法。
Expert Opin Investig Drugs. 2021 Apr;30(4):351-363. doi: 10.1080/13543784.2021.1868437. Epub 2020 Dec 31.
3
Combination therapy of dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer.达拉非尼联合曲美替尼治疗BRAF突变型胆管癌患者
Hepatobiliary Pancreat Dis Int. 2021 Oct;20(5):506-507. doi: 10.1016/j.hbpd.2020.12.010. Epub 2020 Dec 9.
4
BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.BILCAP 试验与可切除胆道癌的辅助卡培他滨治疗：对一种标准治疗方案的思考。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):483-485. doi: 10.1080/17474124.2021.1864325. Epub 2020 Dec 18.
5
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.英菲格拉替尼（BGJ398）：一种用于治疗 FGFR 改变的肝内胆管癌的研究药物。
Expert Opin Investig Drugs. 2021 Apr;30(4):309-316. doi: 10.1080/13543784.2021.1864320. Epub 2021 Jan 4.
6
The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.分子图谱对胆管癌临床试验及实验性药物的影响。
Expert Opin Investig Drugs. 2021 Apr;30(4):281-284. doi: 10.1080/13543784.2021.1849139. Epub 2020 Nov 23.
7
Recent advances of immunotherapy for biliary tract cancer.免疫治疗在胆管癌中的最新进展。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8.
8
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.呋替尼，一种用于治疗肝内胆管癌的研究药物：现有证据和未来展望。
Expert Opin Investig Drugs. 2021 Apr;30(4):317-324. doi: 10.1080/13543784.2021.1837774. Epub 2020 Oct 25.
9
The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?胆管癌（BTC）中的DNA损伤修复（DDR）途径：一个新的潘多拉魔盒？
ESMO Open. 2020 Sep;5(5):e001042. doi: 10.1136/esmoopen-2020-001042.
10
FGFR inhibitors in cholangiocarcinoma: what's now and what's next?胆管癌中的FGFR抑制剂：现状与未来？
Ther Adv Med Oncol. 2020 Sep 16;12:1758835920953293. doi: 10.1177/1758835920953293. eCollection 2020.

晚期胆管癌的新型靶向治疗

Novel Targeted Therapies for Advanced Cholangiocarcinoma.

作者信息

Rizzo Alessandro, Brandi Giovanni

机构信息

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, 40138 Bologna, Italy.

Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

出版信息

Medicina (Kaunas). 2021 Feb 26;57(3):212. doi: 10.3390/medicina57030212.

DOI:10.3390/medicina57030212
PMID:33652960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7996824/
Abstract

Cholangiocarcinoma (CCA) includes a group of rare and aggressive hepatobiliary malignancies, including extrahepatic cholangiocarcinoma (eCCA) and intrahepatic cholangiocarcinoma (iCCA), with the former further subdivided into distal (dCCA) and perihilar cholangiocarcinoma (pCCA) [...].

摘要

胆管癌（CCA）包括一组罕见且侵袭性强的肝胆恶性肿瘤，包括肝外胆管癌（eCCA）和肝内胆管癌（iCCA），前者进一步细分为远端胆管癌（dCCA）和肝门周围胆管癌（pCCA）[...]。